Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL 2018 for children and adolescents with lymphoblastic lymphoma
NL-OMON54528Phase 3Recruiting
- Sponsor
- Universitätsklinikum Münster
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexamethasone, prednisone, pegaspargase and methotrexate in lymphoblastic lymphoma (LL) (4 arms), sponsored by Universitätsklinikum Münster. Primary endpoints: Cumulative incidence of CNS relapse and Event-free survival. Started Jun 2021; status: recruiting.
02
Drugs
dexamethasoneprednisonepegaspargasemethotrexate
03
Conditions
lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NL-OMON54528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54528.